Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quarterly subcutaneous canakinumab to prevent recurrent cardiovascular events after myocardial infarction in patients with elevated hsCRP
jRCT2080221486Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and cardiac morbidity comparing Canakinumab with Placebo (2 arms). Started Jun 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
myocardial infarction (MI)cardiac morbidity
Beyond the preview
Go deeper on jRCT2080221486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221486.